Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2 , 6)- and (5 R )-Methyl-(2 R, 6 R )-hydroxynorketamines.

( R,S )-Ketamine is rapidly metabolized to form a range of metabolites in vivo , including 12 unique hydroxynorketamines (HNKs) that are distinguished by a cyclohexyl ring hydroxylation at the 4, 5, or 6 position. While both (2 R, 6 R )- and (2 S, 6 S )-HNK readily penetrate the brain and exert rapid antidepressant-like actions in preclinical tests following peripheral administration, the pharmacokinetic profiles and pharmacodynamic actions of 10 other HNKs have not been examined. We assessed the pharmacokinetic profiles of all 12 HNKs in the plasma and brains of male and female mice and compared the relative potencies of four (2 , 6)-HNKs to induce antidepressant-relevant behavioral effects in the forced swim test in male mice. While all HNKs were readily brain-penetrable following intraperitoneal injection, there were robust differences in peak plasma and brain concentrations and exposures. Forced swim test immobility rank order of potency, from most to least potent, was (2 R, 6 S )-, (2 S, 6 R )-, (2 R, 6 R )-, and (2 S, 6 S )-HNK. We hypothesized that distinct structure-activity relationships and the resulting potency of each metabolite are linked to unique substitution patterns and resultant conformation of the six-membered cyclohexanone ring system. To explore this, we synthesized (5 R )-methyl-(2 R, 6 R )-HNK, which incorporates a methyl substitution on the cyclohexanone ring. (5 R )-Methyl-(2 R, 6 R )-HNK exhibited similar antidepressant-like potency to (2 R, 6 S )-HNK. These results suggest that conformation of the cyclohexanone ring system in the (2 , 6)-HNKs is an important factor underlying potency and that additional engineering of this structural feature may improve the development of a new generation of HNKs. Such HNKs may represent novel drug candidates for the treatment of depression.